TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: neuroQWERTY index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Survival of implants and bridges
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of Diaphragmatic Hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Healed Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients on ASA
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total radioactivity in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of GLPG0634 and its main metabolites in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of metabolites in plasma, urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of radioactivity, GLPG0634 and its main metabolites in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in apolipoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change in the neuropathy impairment score lower limbs (NISLL+7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Percent Change in Total Volumetric Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-op pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With a Grade 3 or Higher Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of inflammasomes and their active products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Static Eye Gaze Following Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Eye Gaze Following Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social/Visual Attention Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of conclusive diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Any Grade ≥ 1 Laboratory Abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Prematurely Discontinued Study Drug or Study Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Plasma Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Peak Plasma Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Background-corrected Trough Plasma Nicotine Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With CARS Mental Health Diagnoses Made in the ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Psychiatry Evaluations in the Emergency Department (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Mental Health Referrals Made From the ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Rectal ACF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic recurrence or disease recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of improvement of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Oxygen Uptake (VO2) Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One Repetition Maximum- Leg Press
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coping ability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Asthma Control Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Children's Depression Rating Scale - Revised (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean difference of Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hb Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence with the trial interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Evaluation of the EQ5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CSF proteome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive intracuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care behaviors with arteriovenous fistula in hemodialysis
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of suicide attempt resulting in medical encounter or hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Acute rejection biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Early VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Late VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Nasal Carriage of SA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Kidney delayed graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tenofovir diphosphate (TFV-DP) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in symptoms of pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in symptoms of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of subjects achieving a one-point increase on GAIS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Daily Fatigue Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in mucosal expression of renin-angiotensin components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Index of microcirculatory resistance of infarct-related artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of BAY1143572
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Total Observed Drug Concentration (Cmax) after Single Dose Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-24h]) after Single Dose Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Berg Balance Scale (BBS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of Vero cell derived vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Life Quality Index (LQI) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Asthma Severity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ABCA1 mRNA expression in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke and TIA
Endpoint domain: Mortality/survival
Primary endpoint: Aneurysm-related death
Endpoint domain: Mortality/survival
Primary endpoint: MEP amplitude at S50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with a PGSGA score ≥4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the patient's condition clinically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the patient's condition radiologically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Thickness gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin (HgB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hydromorphone Use at 24 Hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity and specificity of MR Arthrograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of genetic counseling sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: depression post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: depression at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: depression at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Asthma Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalization of Fever and Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure reactivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Who Relapsed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TceMEP amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TceMEP latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of warfarin and ISIS 681257
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza Diagnostic test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tumor Marker Cancer Antigen-125 (CA-125)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Response Rate (ORR) by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Wrinkle Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of Milk allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: depletion of blood SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in home systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in home diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percent Change in Wound Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in diabetes self-management behaviours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: relief of chronic low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Timed 25 Feet Walking Test (T25FW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of postoperative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Varenicline
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Morbidity (Major Complications)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and efficacy of the exercise training program
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported acute diabetes complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allograft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Antibiotic Courses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Hospitalisations Due to Respiratory Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of severe complications (grade 3 or more)
Endpoint domain: Adverse events/effects
Primary endpoint: User performance of blood glucose monitoring systems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: toxicity analysis
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy analysis
Endpoint domain: Physiological/clinical
Primary endpoint: Echocardiographic changes (diastolic dysfunction & pericardial effusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ECG changes (QT interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Technical Success of Delivery of the Transcaval Closure Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Biopsy Cores in Which Prostate Cancer Was Detected Using Subharmonic Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects With Previously Unidentified Prostate Cancer Using Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increased pedometer steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of firmicutes to bacteroidetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KT width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dendritic cells accumulating in the dermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of the sentinel node occupied by dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of deafness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Street Crossings Distracted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accretion of EPA in erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in renal function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax of Fimasartan, Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Fimasartan, Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alanine transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical response induced by belimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined index positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Carotid Intima Media Thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in z-score muscle power during a two leg jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Forefoot deformity prevalence during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absence of Gastric and/or Duodenal Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric mean titer (GMT) seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uptake of FLT in hematological bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microbial Eradication of Baseline Bacterial Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in physical activity-related health competence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Head Images Successfully Collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Progression-free Survival rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Severe endoscopic recurrence of Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of 4-fold or greater serum hemagglutination inhibition assay (HAI) and neutralizing antibody rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in sexual health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in subcutaneous flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Urea Breath Test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time-curve From Zero to Extrapolated Infinite Time (AUC[0-inf]) of Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Resection Margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absolute change in office systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with a vasculitis response at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with a severe adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Homeostatic model assessment and insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in ASM Mass Between Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in ASM Proliferation, Migration and Cytokine Release Between Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Intracellular Oxidative Stress Mechanisms From ASM Between Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity spectrum and dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical activity in terms of radiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker Measurement of phosphorylated neurofilament heavy chain (pNfH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biomarker Measurement of complement C3 in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: post operative pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: All cause emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maintain glucose range goal of 90-120 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintain at least 90% of glucose values within the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Have fewer than 1% of glucose values below 50 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Avastin treatment discontinuation due to disease progression
Endpoint domain: Adverse events/effects